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CASE REPORT
Compound heterozygous RMND1 gene 
variants associated with chronic kidney disease, 
dilated cardiomyopathy and neurological 
involvement: a case report
Asheeta Gupta1, Isabel Colmenero1, Nicola K. Ragge2,3, Emma L. Blakely4, Langping He4, Robert McFarland4, 
Robert W. Taylor4, Julie Vogt2 and David V. Milford1*
Abstract 
Background: Nuclear gene mutations are being increasingly recognised as causes of mitochondrial disease. The 
nuclear gene RMND1 has recently been implicated in mitochondrial disease, but the spectrum of pathogenic variants 
and associated phenotype for this gene, has not been fully elucidated.
Case presentation: An 11-month-old boy presented with renal impairment associated with a truncal ataxia, bilateral 
sensorineural hearing loss, hypotonia, delayed visual maturation and global developmental delay. Over a 9-year 
period, he progressed to chronic kidney disease stage V and developed a dilated cardiomyopathy. Abnormalities in 
renal and muscle biopsy as well as cytochrome c oxidase activity prompted genetic testing. After exclusion of mito-
chondrial DNA defects, nuclear genetic studies identified compound heterozygous RMND1 (c.713A>G, p. Asn238Ser 
and c.565C>T, p.Gln189*) variants.
Conclusion: We report RMND1 gene variants associated with end stage renal failure, dilated cardiomyopathy, deaf-
ness and neurological involvement due to mitochondrial disease. This case expands current knowledge of mito-
chondrial disease secondary to mutation of the RMND1 gene by further delineating renal manifestations including 
histopathology. To our knowledge dilated cardiomyopathy has not been reported with renal failure in mitochondrial 
disease due to mutations of RMND1. The presence of this complication was important in this case as it precluded 
renal transplantation.
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Background
Mitochondrial disorders are amongst the most common 
inborn errors of metabolism, with an estimated preva-
lence of 1 in 5000 live births [1]. Renal involvement is 
common either in isolation or as part of a multisystem 
disease. Knowledge of the genetic basis to mitochondrial 
disease has progressed significantly over the past 5 years 
and continues to evolve [2, 3]. It is now recognised that 
these diseases can be caused by nuclear as well as mito-
chondrial gene mutations, thus maternal inheritance pat-
terns are not always seen. The ongoing identification of 
pathogenic nuclear mutations has broadened the spec-
trum of nuclear mitochondrial disease [2].
Mitochondrial cytopathy due to nuclear gene muta-
tions is becoming increasingly more important for neph-
rologists to recognise since there may be potential for 
reversibility of some conditions that are caused by coen-
zyme Q10 biosynthesis defects [3] as well as the implica-
tion for treatment options, including renal transplant.
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Several nuclear gene mutations have been identified 
in mitochondrial cytopathies with renal involvement [4, 
5]. Renal involvement in these cases usually manifests 
as nephrotic syndrome or tubulopathies [4, 5]. Chronic 
kidney disease is a less common phenotype of nuclear 
mitochondrial gene mutations and has been reported in 
cases caused by mutations in COQ2, SARS2 and recently 
in RMND1 genes. Mutation of COQ2 causes a Coen-
zyme Q10 (ubiquinone) deficiency and steroid resistant 
focal segmental glomerulosclerosis (FSGS) leading to end 
stage renal failure [6]. The SARS2 gene is thought to be 
involved in mitochondrial translation. Gene mutations 
in SARS2 result in hyperuracaemia, pulmonary hyper-
tension, infantile renal failure and alkalosis (HUPRA 
syndrome) [7, 8]. Recently, the nuclear encoded RMND1 
gene has been implicated in causing mitochondrial dis-
ease of varying severity, manifesting in profound deaf-
ness and neurological involvement with or without renal 
and cardiac manifestations [9, 10]. The specific cardiac 
manifestations have not been published. Renal disease 
has comprised of renal dysplasia [2], renal tubular aci-
dosis [2] and chronic kidney disease associated with pro-
teinuria [9, 10]. Underlying histopathological diagnosis is 
yet to be described in these patients with chronic kidney 
disease. Though specific function of the RMND1 protein 
is not completely known; it is encoded by a nuclear gene 
and interestingly, has also been proposed to be essential 
for mitochondrial translation [11, 12].
We describe the natural history of a child’s phenotype 
associated with mutations in a nuclear gene implicated 
in mitochondrial protein synthesis causing mitochon-
drial disease with renal, cardiac and neuromuscular 
involvement.
Case presentation
An 11-month-old Caucasian boy was referred to this 
department for investigation of a raised urea and cre-
atinine. He was born at 37 weeks’ gestation to unrelated 
parents. He had difficulties with bottle-feeding in the 
first 2  weeks of life and at the time of weaning he was 
noted to choke on solids. He was also found to have 
bilateral profound sensorineural hearing loss on routine 
screening, which led to him receiving cochlear implants 
at 18 months. At 8 weeks, he was not fixing and follow-
ing and was noted to be hypotonic. At 10  months, he 
became unwell with fever, lethargy and rash. His urea 
was 44 mmol/L but reduced to 14 mmol/L after rehydra-
tion therapy.
At the time of his referral he had global developmen-
tal delay, truncal hypotonia, delayed visual maturation 
and bilateral sensorineural hearing loss. He was not on 
any regular medication. Results of initial blood and urine 
tests together with serial plasma lactate levels from pres-
entation are shown in Fig. 1 and Table 1 respectively.
A renal ultrasound scan showed right and left renal 
lengths were 6.2 cm (30th centile) and both kidneys were 
echogenic. The presence of renal impairment and echo-
genic kidneys on ultrasound prompted renal biopsy, 
which showed significant tubulointerstitial damage with 
immature glomeruli (Fig.  2a, b). Electron microscopy 
of renal tissue revealed abnormal mitochondria affect-
ing the tubular cells (Fig.  2c). Assessment of oxidative 
enzyme histochemistry in a muscle biopsy revealed a 
mosaic pattern of cytochrome c oxidase (COX) activity 
(Fig. 2d), which was confirmed by direct measurement of 
respiratory chain enzyme activities; complexes I and IV 
were both severely decreased with complex III activity 
decreased to a lesser extent, and evidence of complex II 
activity being spared (Fig. 2e). Taken together, these data 
are consistent with a generalised disorder of mitochon-
drial function.
Brain magnetic resonance imaging (MRI) of the 
proband was reported to show abnormal signal in the 
cerebral white matter particularly in the temporal and 
subcortical white matter in the frontal lobes and abnor-
mal signal in the periventricular white matter around the 
trigone and frontal horns. A cystic area was also seen in 
the temporal lobe. The features were in keeping with a 
metabolic condition or megalencephalic leukoencepha-
lopathy with subcortical cysts.
Abnormal findings from kidney and muscle biopsy 
prompted genetic testing for mitochondrial disease. 
Diagnostic mitochondrial DNA (mtDNA) studies, 
including assessment of mtDNA copy number, mtDNA 
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Fig. 1 Plasma lactate profile from 11 months of age (time of 
presentation to nephrology) to present. The markedly raised plasma 
lactate level in 2010 (indicated by an asterisk) was during a period of 
transient inter-current viral illness
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rearrangements and sequencing of the entire mito-
chondrial genome were all normal (data not shown). 
Due to a strong clinical suspicion of mitochondrial dis-
ease, nuclear genetic studies were undertaken, prior-
itising the analysis of the RMND1 gene because of the 
clinical presentation. Direct Sanger sequencing of the 
RMND1 coding exons in blood genomic DNA (primer 
sequences and conditions available on request from the 
authors) identified two heterozygous RMND1 (GenBank 
Accession number NM_017909.2) variants predicted 
to be deleterious—a rare c.713A>G, p.Asn238Ser mis-
sense change (21/120626 alleles on ExAC and 5/12982 
alleles on ESP6500) affecting a highly conserved residue 
and a novel c.565C>T, p.Gln189* truncating mutation. 
Analysis of parental blood DNA samples confirmed the 
mother carried the c.713A>G, p.Asn238Ser variation 
and the father carried the c.565C>T, p.Gln189* varia-
tion, thus demonstrating recessive inheritance (Fig.  2f ). 
The p.Asn238Ser mutation has recently been shown by 
others to be a pathogenic RMND1 variant [10]. During 
this period of investigation the patient was commenced 
on Coenzyme Q10 supplementation. Despite starting this 
supplement our proband remained globally delayed in 
terms of his development.
This child demonstrated stable chronic kidney disease 
(CKD) for 9  years since presentation. Plasma creati-
nine started to increase at the age of 10 years, indicating 
a decline in renal function (Fig.  3). At this time he was 
hospitalized for a gastroenteritic illness and cardiovascu-
lar examination revealed peripheral oedema and a gallop 
rhythm on auscultation. His echocardiogram confirmed 
a diagnosis of a dilated cardiomyopathy (ejection fraction 
of 35 %) for which he was given diuretics. His renal func-
tion failed to improve and he has commenced peritoneal 
dialysis.
Conclusion
We report the case of a child found to harbour com-
pound heterozygous variants in the RMND1 gene, who 
presented with global developmental delay, truncal 
hypotonia, bilateral sensorineural hearing loss and renal 
impairment. He had stable CKD, but later had deteriora-
tion in renal function and required dialysis complicated 
by a dilated cardiomyopathy.
RMND1 gene mutations have been linked to mito-
chondrial disease with varying severity and variable 
multisystem involvement [2, 9–13]. However, all cases 
presented with deafness and some element of neuro-
muscular disease. Of the published cases to date, seven 
had additional renal involvement and presented at or 
earlier than 18  months of age. This comprised of renal 
dysplasia in two patients homozygous for c.1349G>C, 
p.450Serext*32 stop-extension RMND1 mutation, one 
of which also had cardiac involvement [2]. The same 
homozygous mutation was found in a third patient with 
renal tubular acidosis, cardiac involvement and seizures 
who died at the age of 10  years. Further details on the 
type of cardiac involvement have not been published [2]. 
A further case found to have renal tubular acidosis and 
seizures had a different compound heterozygous muta-
tion (c.713A>G, p.Asn238Ser/c.829_830  +  2delGAGT, 
p.Glu277Glyfs*2). Three cases presented with renal fail-
ure and compound heterozygous mutations involving 
c.713A>G p.Asn238Ser together with other different 
mutations, as in our case. Two of these cases presented 
at birth, one with severe myopathy, dysautonomia, lac-
tic acidosis, deafness and renal failure. This case also had 
abnormal brain MRI findings with delayed myelination 
and abnormal post periventricular white matter signal 
[9]. The other presented with hypotonia, intellectual dis-
ability deafness, renal failure and abnormal brain MRI 
with loss of white matter in the temporal lobes [10]. The 
final case presented at 14 months with hypotonia, intel-
lectual disability, lactic acidosis, deafness and renal fail-
ure with a normal MRI brain [10]. The latter two patients 
Table 1 Initial blood and urine results taken at 11 months 
of age
Abnormal results are highlighted in italics
Test Result
Blood
 Sodium 135 mmol/L (135–145 mmol/L)
 Potassium 5.4 mmol/L (3.5–5.5 mmol/L)
 Urea 20.9 mmol/L (2.0–6.2 mmol/L)
 Creatinine 72 micromol/L
 Adjusted calcium 2.58 mmol/L (2.1–2.5 mmol/L)
 Phosphate 1.57 mmol/L (1.3–2.3 mmol/L)
 Bicarbonate 18.8 mmol/L (23–29 mmol/L)
 Magnesium 1.45 mmol/L (1.6–2.6 mmol/L)
 Total bilirubin <5 micromol/L (<5 micromol/L)
 Alkaline phosphatase 474 IU/L (110–320 IU/L)
 Alanine transferase 21 IU/L (6–45 IU/L)
 Albumin 43 g/L (35–50 g/L)
 Ammonia 25 micromol/L (22–48 micromol/L)
 Lactate 4.8 mmol/L (0.2–2.0 mmol/L)
 Parathyroid hormone 114 nanogram/L (10–65 nanogram/L)
Urine
 Urine protein/creatinine 16 mg/mmol (<50 mg/mmol)
 Urine albumin/creatinine <1.93 mg/mmol (<1.93 mg/mmol)
 Urine retinol binding protein <2.0 mg/L (<2.0 mg/L)
 Urine amino acids and organic 
acids
Normal
Other
 Cerebrospinal fluid lactate 2.2 mmol/L 0.6–2.2 mmol/L
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were sisters. Both developed CKD and hypertension in 
the first decade of life. Both had proteinuria, but it is not 
known to what extent. Renal ultrasound revealed normal 
sized kidneys with normal echogenicity. Unfortunately 
neither underwent renal biopsy. They both underwent 
renal transplant successfully. Our proband did not have 
proteinuria and presented with renal impairment in 
infancy, with a very slow progression to ESRF. The devel-
opment of dilated cardiomyopathy prevented renal trans-
plant, which was being considered prior to this point. It 
is interesting that none of the three patients with renal 
failure have any reported cardiac involvement [9, 10].
Mitochondrial diseases classically vary in their 
severity, rate of progression and system involvement. 
Those with severe multisystem involvement and poor 
prognosis often present early in childhood (although 
there are exceptions) and most of these cases do not 
survive beyond childhood. Cases presenting later in 
childhood or adulthood often have less severe pheno-
types and are more likely to be associated with mtDNA 
point mutations. Some individuals may have isolated 
renal involvement at presentation and have a better 
prognosis, for example those with the m.3243A>G 
point mutation, who often present later with proteinu-
ria and go on to be diagnosed with FSGS [14]. These 
individuals may survive into adulthood, but many 
require renal replacement therapy and can be success-
fully transplanted [15, 16].
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Fig. 2 a, b Renal biopsy taken at time of presentation (11 months of age) showing moderate tubulointerstitial damage and numerous immature 
glomeruli (arrow) (a). Masson trichrome, ×100 (b) (silver, ×200). c Electron Micrograph of renal biopsy: A tubular epithelial cell showing mildly 
enlarged mitochondria with a fluffy granular matrix (arrow). d Assessment of oxidative enzyme histochemistry in a muscle biopsy revealed a mosaic 
pattern of cytochrome c oxidase (COX) activity. Presence of fibres with subsarcolemmal aggregates of mitochondria (arrow) and some type II fibres 
devoid of activity (asterisk) (×600). e The assessment of individual respiratory chain enzyme activities in muscle identified a combined OXPHOS 
deficiency in the patient (blue bars) compared to controls (red bars); mean enzyme activities shown for muscle controls (n = 25) are set at 100 %. 
The activities of complexes I and IV were both severely decreased with complex III activity decreased to a lesser extent, and evidence of complex II 
activity being spared. f Familial segregation of the identified compound heterozygous RMND1 variants, a paternally-inherited p.Asn238Ser variant 
and a maternally-inherited p.Gln189* variant
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Sadly, a major characteristic of mitochondrial cytop-
athy is the unpredictability and progressive nature of 
systemic involvement. Rotig et al. [17] reported a child 
with mitochondrial cytopathy due to a nuclear gene 
mutation affecting the coenzyme Q10 pathway. This 
patient had bilateral sensorineural deafness, nystag-
mus and nephrotic syndrome that led to end stage renal 
failure (ESRF) but who successfully underwent a renal 
transplant. The patient subsequently suffered neuro-
logical deterioration after transplantation rendering 
him unable to walk; this was successfully treated with 
ubiquinone. Hameed et  al. [18] described a 6  year old 
boy with hypoparathyroidism, muscle weakness, sen-
sorineural deafness and FSGS who progressed to estab-
lished renal failure and who was successfully dialysed 
and transplanted, but suffered a neurological deterio-
ration 4  years later. This child was clinically diagnosed 
with mitochondrial cytopathy and he later died of res-
piratory failure from progressive muscle weakness. 
These cases highlight the complex issues of treating 
established renal failure in children with mitochondrial 
cytopathies because they may subsequently develop life-
limiting complications as a result of disease progression. 
However, given the rate of progression in mitochondrial 
disease is variable and unpredictable, organ transplan-
tation should be considered in the overall context of 
health needs and issues. Where possible, genetic confir-
mation and expert clinical advice on the mitochondrial 
disease course would be important contributions to the 
decision-making process.
Our patient presented at a young age and had a clini-
cal diagnosis of a mitochondrial disease that has only 
recently been genetically defined. He has shown a grad-
ual decline in renal function over the past 9 years. Unfor-
tunately, he developed a cardiomyopathy with a poor 
ejection fraction of 35  %, which precludes renal trans-
plant and has raised difficult clinical and ethical issues 
regarding his long-term renal replacement treatment. 
The genetic testing in this case was revisited after the ini-
tial panel of known mutations was negative. Identifying 
the genetic mutation not only helped to confirm the diag-
nosis but also in decision making regarding therapeutic 
options and counseling the family regarding prognosis. 
Hence, with expanding knowledge of new mutations 
linked to mitochondrial disease pursuing a genetic 
diagnosis in cases where there is a clinical suspicion is 
worthwhile.
We describe the phenotype of a child with novel com-
pound heterozygous RMND1 gene variants and mito-
chondrial disease causing multisystem failure including 
renal failure and cardiomyopathy. This report emphasizes 
the value of pursuing a genetic diagnosis in such cases to 
aid decisions regarding therapeutic options and coun-
seling of patients and their families.
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